Sirolimus outperforms alpelisib in models of NRASQ61R-driven vascular overgrowth
Svatava Merkle(Cincinnati Children's Hospital Medical Center), Timothy D. Le Cras(Cincinnati Children's Hospital Medical Center), Sara Alharbi(Cincinnati Children's Hospital Medical Center), Patricia Pastura(Cincinnati Children's Hospital Medical Center), C. Griffin McDaniel(Cincinnati Children's Hospital Medical Center)
Cited by 0
Related Papers
Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis
|American Journal Of Pathology|2009|62
Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation
|Angiogenesis|2020|55
How we use angiopoietin‐2 in the diagnosis and management of vascular anomalies
|Pediatric Blood & Cancer|2024|14
NRAS <sup>Q61R</sup> mutation drives elevated angiopoietin‐2 expression in human endothelial cells and a genetic mouse model
|Pediatric Blood & Cancer|2024|13
RAS Pathway Mutations and Therapeutics in Vascular Anomalies
|Pediatric Blood & Cancer|2025|11